CytomX Therapeutics: Varseta-M Phase 1 expansion data Q1 2026, initial data by 1H 2027.

Thursday, Jan 8, 2026 8:14 am ET1min read
CTMX--

CytomX Therapeutics announced a business update and anticipated milestones for 2026. The company expects CX-2051 expansion data for colorectal cancer in Q1 2026, while the Varsetatug masetecan Phase 1 combination study with bevacizumab will start in Q1 2026 with initial data expected by 1H 2027. Initial CX-801 Masked Interferon-alpha-2b Phase 1 combination data with KEYTRUDA in melanoma is expected by the end of 2026. CytomX will present at the 44th Annual JP Morgan Healthcare Conference on January 14th.

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet